Daniel Tenen

By Alice McCarthy A recent paper published in New England Journal of Medicine reveals that treatment of myelodysplastic syndrome (MDS) with hypomethylating agents (HMAs) activates a sleeping oncogene, leading to poorer survival. This discovery raises the...

HSCI physician-scientists Daniel Tenen and Li Chai want to turn off a gene to stop cancer without poisoning the patient. The ideal cancer drug would harm cancer cells without hurting normal cells. In their quest to discover one good therapy, HSCI...

Therapeutic has applications in treating liver cancers and leukemias By Jessica Lau Summary Scientists have engineered a therapeutic molecule that blocks SALL4, a protein involved in about one-third of cancers, in mice. This therapeutic approach could be...

Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), in collaboration with Harvard Stem Cell Institute (HSCI), have discovered a new way in which the development of lung cancer can be...

An international team of researchers working in the Boston and Singapore labs of Harvard Stem Cell Institute (HSCI) Blood Program leader Daniel Tenen, MD, recently identified new candidates for the treatment of an acute myeloid leukemia (AML) subtype...

Harvard Stem Cell Institute (HSCI) researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity. The gene, SALL4, gives...

Harvard Stem Cell Institute (HSCI) researchers have settled a century-old debate over whether occurrence of DNA methylation acts to silence gene expression, or if genes are turned off by other means before they are methylated. As explicated today in the...